Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Leqembi and Kisunla are given as an intravenous (IV) infusion, meaning patients and caretakers often must travel to specialty health centers once or twice a month for an infusion. That could soon ...

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms ...

rather than in an infusion clinic. Eisai and Biogen's filing is for a once-weekly autoinjector formulation of Leqembi (lecanemab) that would be used after a biweekly IV initial induction course ...

Leqembi is designed to slow the progression ... The drug is also given as an intravenous infusion that takes an hour every two weeks. But Viehbacher told investors at the meeting that three ...

Q3 2024 Management View CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included ...

Leqembi’s launch in the US has been slow due to a variety of factors including regular infusion logistics and diagnosis constraints. Eisai estimated at the time of its sales call that 10,000 ...

Key contributors included LEQEMBI with a 28.1 billion yen increase ... The company expects further expansion of infusion capacity and patient access in the US, supported by increased Amyloid ...

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms ...